Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 17, 2002

View Archived Issues

Biovation and Viventia collaborate to design novel nonimmunogenic protein therapeutic

SRI SERM selected for NCI development program

Potential use of midostaurin in chemotherapy-resistant leukemias

Novel orexin-1 receptor antagonists in GSK development pipeline

U. of Padova researchers design novel antitumor aloe-emodin derivatives

News series of iNOS inhibitors under study at AstraZeneca

Novartis patent covers new VEGFR inhibitors for cancer, pain, etc.

New data on liposomal vincristine combined with rituximab in leukemia

Potential use of CC-5013 in the treatment of hematological malignancies

Kirin Brewery designs new urea-based antitumor agents

New PGI2 agonists with utility in antiplatelet therapy discovered at Nippon Kayaku

CholeraGarde vaccine enters phase II trial in Bangladesh

Lilly seeks expanded indication for Gemzar in Europe

Cellular Genomics enters kinase R&D collaboration with Schering AG

TP-38 demonstrates antitumor activity in glioblastoma

European orphan drug designation recommended for Xyrem

AMD-3100 enters phase II in combination with G-CSF for stem cell transplantation

Medarex acquires anti-PSMA antibody rights from Northwest Biotherapeutics

Phase II trial assesses ETC-588 in acute coronary syndromes

Renovis acquires Centaur's assets

Spectrum expands Neoquin study in superficial bladder cancer

Monoclonal antibody targeting chemokine receptor advances to clinical evaluation

Data supporting use of Risperdal for bipolar disorder submitted to FDA

Small-molecule XIAP antagonist identified by La Jolla-based team

Pharmacokinetics and safety of oral SPM-927 reported at American Epilepsy Society meeting

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...